– UK, London – Smith+Nephew Plc (LON: SN / NYSE: SNN), the global medical technology company, announced the appointment of Sybella Stanley to its Board as an Independent Non-Executive Director, effective 1 February 2025.
“We are delighted to welcome Sybella to our Board. Her broad experience in successful global businesses in both senior management and non-executive capacities will further strengthen the Board. This appointment reflects Smith+Nephew’s commitment to succession planning, bringing together a range of diverse talent, expertise, skills, and experience, and ensuring the effective transition of responsibilities.” said Board Chair, Rupert Soames.
Sybella will join the Remuneration Committee and will succeed Angie Risley as Chair, effective 30 June 2025.
About Sybella Stanley
Sybella Stanley has worked for RELX Plc since 1997 and is Director of Corporate Finance. She retired in December 2024 from the Board of Tate & Lyle plc, where she served for nine years as an Independent Non-Executive Director and Chair of the Remuneration Committee. Additionally, she served for nine years as an Independent Non-Executive Director of Merchants Trust PLC, including as Senior Independent Director and Chair of the Remuneration Committee, until her retirement in March 2024. Sybella is also co-chair of the Development Board of Somerville College, Oxford.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration, and replacement of soft and hard tissue. The company exists to restore people’s bodies and their self-belief by using technology to take the limits off living. This purpose is called ‘Life Unlimited’.
With 18,000 employees globally, Smith+Nephew makes a difference in patients’ lives through its product portfolio and the invention and application of new technologies across its three global business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
- Founded in Hull, UK, in 1856, Smith+Nephew now operates in more than 100 countries.
- The company generated annual sales of $5.5 billion in 2023.
- Smith+Nephew is a constituent of the FTSE100 (LON: SN, NYSE: SNN).
For more: https://www.smith-nephew.com/en
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.